Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600131822) titled 'A Prospective, Open-Label, Multicenter Clinical Study of Intravenous Disitamab Vedotin Combined with Intravesical Gemcitabine for HER2-Expressing High-Risk Non-Muscle Invasive Bladder Cancer' on Sept. 7.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Lishui Central Hospital

Condition: Malignant neoplasm of bladder

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2026-09-07

Target Sample Size: Experimental group:40;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=325063

Published by HT Digital Conte...